ReP USP - Resultado da busca

Artigo de periodico
Prospective prediction of Dapaconazole Clinical Drug–Drug interactions using an in vitro to in vivo extrapolation equation and PBPK modeling (2023)
Antunes, Natalícia de Jesus ; Moreira, Fernanda de Lima ; Kipper, Karin ; Couchman, Lewis ; Lebre, Daniel Temponi ; Johnston, Atholl ; De Nucci, Gilberto
Source: Pharmaceuticals. Unidade: ICB
Subjects: FARMACOLOGIA, CITOCROMO P-450, ENZIMAS OXIRREDUTORAS, ANTIFÚNGICOS, INTERAÇÃO DE MEDICAMENTOS, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ANTUNES, Natalícia de Jesus et al. Prospective prediction of Dapaconazole Clinical Drug–Drug interactions using an in vitro to in vivo extrapolation equation and PBPK modeling. Pharmaceuticals, v. 16, n. 1, p. 1-15, 2023Tradução . . Disponível em: https://doi.org/10.3390/ph16010028. Acesso em: 14 nov. 2024.
APA
Antunes, N. de J., Moreira, F. de L., Kipper, K., Couchman, L., Lebre, D. T., Johnston, A., & De Nucci, G. (2023). Prospective prediction of Dapaconazole Clinical Drug–Drug interactions using an in vitro to in vivo extrapolation equation and PBPK modeling. Pharmaceuticals, 16( 1), 1-15. doi:10.3390/ph16010028
NLM
Antunes N de J, Moreira F de L, Kipper K, Couchman L, Lebre DT, Johnston A, De Nucci G. Prospective prediction of Dapaconazole Clinical Drug–Drug interactions using an in vitro to in vivo extrapolation equation and PBPK modeling [Internet]. Pharmaceuticals. 2023 ; 16( 1): 1-15.[citado 2024 nov. 14 ] Available from: https://doi.org/10.3390/ph16010028
Vancouver
Antunes N de J, Moreira F de L, Kipper K, Couchman L, Lebre DT, Johnston A, De Nucci G. Prospective prediction of Dapaconazole Clinical Drug–Drug interactions using an in vitro to in vivo extrapolation equation and PBPK modeling [Internet]. Pharmaceuticals. 2023 ; 16( 1): 1-15.[citado 2024 nov. 14 ] Available from: https://doi.org/10.3390/ph16010028
Artigo de periodico
Studies on metal–organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension (2021)
Mohamed, Nura A.; Saleh, Haissam Abou ; Kameno, Yu; Marei, Isra ; De Nucci, Gilberto ; Shala, Blerina Ahmetaj ; Shala, Fisnik; Kirkby, Nicholas S. ; Jennings, Lewis ; Ansari, Dana E. Al; Davies, Robert P. ; Lickiss, Paul D.; Mitchell, Jane A.
Source: Scientific Reports. Unidade: ICB
Subjects: FARMACOLOGIA, HIPERTENSÃO PULMONAR, AORTA DE ANIMAL, CAMUNDONGOS, CÉLULAS ENDOTELIAIS, MÚSCULO LISO VASCULAR, VASODILATAÇÃO, FÁRMACOS (SISTEMA CARDIOVASCULAR), MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MOHAMED, Nura A. et al. Studies on metal–organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension. Scientific Reports, v. 11, p. 8 , 2021Tradução . . Disponível em: https://doi.org/10.1038/s41598-021-83423-6. Acesso em: 14 nov. 2024.
APA
Mohamed, N. A., Saleh, H. A., Kameno, Y., Marei, I., De Nucci, G., Shala, B. A., et al. (2021). Studies on metal–organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension. Scientific Reports, 11, 8 . doi:10.1038/s41598-021-83423-6
NLM
Mohamed NA, Saleh HA, Kameno Y, Marei I, De Nucci G, Shala BA, Shala F, Kirkby NS, Jennings L, Ansari DEA, Davies RP, Lickiss PD, Mitchell JA. Studies on metal–organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension [Internet]. Scientific Reports. 2021 ; 11 8 .[citado 2024 nov. 14 ] Available from: https://doi.org/10.1038/s41598-021-83423-6
Vancouver
Mohamed NA, Saleh HA, Kameno Y, Marei I, De Nucci G, Shala BA, Shala F, Kirkby NS, Jennings L, Ansari DEA, Davies RP, Lickiss PD, Mitchell JA. Studies on metal–organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension [Internet]. Scientific Reports. 2021 ; 11 8 .[citado 2024 nov. 14 ] Available from: https://doi.org/10.1038/s41598-021-83423-6
Artigo de periodico
6-Nitrodopamine is an endogenous mediator of rat isolated epididymal vas deferens contractions induced by electric-field stimulation (2021)
Britto Júnior, José ; Ximenes, Luiz; Ribeiro, André ; Fregonesi, Adriano ; Campos, Rafael ; Kiguti, Luiz Ricardo de Almeida ; Mónica, Fabíola Zakia ; Antunes, Edson ; De Nucci, Gilberto
Source: European Journal of Pharmacology. Unidade: ICB
Subjects: FARMACOLOGIA, NEOPLASIAS, MEDICAMENTO, INFLAMAÇÃO, ANTI-INFLAMATÓRIOS ESTEROIDES, GLIOMA, NEOPLASIAS CEREBRAIS, CÉLULAS CULTIVADAS DE TUMOR, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRITTO JÚNIOR, José et al. 6-Nitrodopamine is an endogenous mediator of rat isolated epididymal vas deferens contractions induced by electric-field stimulation. European Journal of Pharmacology, v. 911, p. 1-13, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.ejphar.2021.174544. Acesso em: 14 nov. 2024.
APA
Britto Júnior, J., Ximenes, L., Ribeiro, A., Fregonesi, A., Campos, R., Kiguti, L. R. de A., et al. (2021). 6-Nitrodopamine is an endogenous mediator of rat isolated epididymal vas deferens contractions induced by electric-field stimulation. European Journal of Pharmacology, 911, 1-13. doi:10.1016/j.ejphar.2021.174544
NLM
Britto Júnior J, Ximenes L, Ribeiro A, Fregonesi A, Campos R, Kiguti LR de A, Mónica FZ, Antunes E, De Nucci G. 6-Nitrodopamine is an endogenous mediator of rat isolated epididymal vas deferens contractions induced by electric-field stimulation [Internet]. European Journal of Pharmacology. 2021 ; 911 1-13.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.ejphar.2021.174544
Vancouver
Britto Júnior J, Ximenes L, Ribeiro A, Fregonesi A, Campos R, Kiguti LR de A, Mónica FZ, Antunes E, De Nucci G. 6-Nitrodopamine is an endogenous mediator of rat isolated epididymal vas deferens contractions induced by electric-field stimulation [Internet]. European Journal of Pharmacology. 2021 ; 911 1-13.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1016/j.ejphar.2021.174544
Artigo de periodico
A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug (2020)
Wallace, John L. ; Nagy, Peter ; Feener, Troy D.; Allain, Thibault ; Ditrói, Tamás; Vaughan, David J.; Muscará, Marcelo Nicolás (Orientador) ; De Nucci, Gilberto ; Buret, Andre G.
Source: British Journal of Pharmacology. Unidade: ICB
Subjects: FARMACOLOGIA, ENSAIO CLÍNICO, ANTI-INFLAMATÓRIOS, SISTEMA GASTROINTESTINAL, MEDICAMENTO, ANALGÉSICOS, FÁRMACOS GASTRINTESTINAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
WALLACE, John L. et al. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug. British Journal of Pharmacology, n. 4, p. 769-777, 2020Tradução . . Disponível em: https://doi.org/10.1111/bph.14641. Acesso em: 14 nov. 2024.
APA
Wallace, J. L., Nagy, P., Feener, T. D., Allain, T., Ditrói, T., Vaughan, D. J., et al. (2020). A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug. British Journal of Pharmacology, ( 4), 769-777. doi:10.1111/bph.14641
NLM
Wallace JL, Nagy P, Feener TD, Allain T, Ditrói T, Vaughan DJ, De Nucci G, Buret AG. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug [Internet]. British Journal of Pharmacology. 2020 ;( 4): 769-777.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1111/bph.14641
Vancouver
Wallace JL, Nagy P, Feener TD, Allain T, Ditrói T, Vaughan DJ, De Nucci G, Buret AG. A proof‐of‐concept, phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drug [Internet]. British Journal of Pharmacology. 2020 ;( 4): 769-777.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1111/bph.14641
Artigo de periodico
Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids (2020)
Costa, Soraia Katia Pereira ; Muscará, Marcelo Nicolás (Orientador) ; Allain, Thibault ; Dallazen, Jorge Luiz ; Santos, Larissa Gonzaga ; Buret, Andre G.; Vaughan, David J.; Fowler, Christopher J.; De Nucci, Gilberto ; Wallace, John L.
Source: Antioxidants & Redox Signaling. Unidade: ICB
Subjects: FARMACOLOGIA, ANALGÉSICOS, INFLAMAÇÃO, DOR, ÚLCERA GÁSTRICA, SISTEMA GASTROINTESTINAL, ANTI-INFLAMATÓRIOS NÃO ESTEROIDES, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Soraia Katia Pereira et al. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxidants & Redox Signaling, p. 7 , 2020Tradução . . Disponível em: https://doi.org/10.1089/ars.2019.7884. Acesso em: 14 nov. 2024.
APA
Costa, S. K. P., Allain, T., Dallazen, J. L., Santos, L. G., Buret, A. G., Vaughan, D. J., et al. (2020). Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids. Antioxidants & Redox Signaling, 7 . doi:10.1089/ars.2019.7884
NLM
Costa SKP, Allain T, Dallazen JL, Santos LG, Buret AG, Vaughan DJ, Fowler CJ, De Nucci G, Wallace JL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids [Internet]. Antioxidants & Redox Signaling. 2020 ;7 .[citado 2024 nov. 14 ] Available from: https://doi.org/10.1089/ars.2019.7884
Vancouver
Costa SKP, Allain T, Dallazen JL, Santos LG, Buret AG, Vaughan DJ, Fowler CJ, De Nucci G, Wallace JL. Enhanced analgesic effects and gastrointestinal safety of a novel, hydrogen sulfide-releasing anti-inflammatory drug (ATB-352): a role for endogenous cannabinoids [Internet]. Antioxidants & Redox Signaling. 2020 ;7 .[citado 2024 nov. 14 ] Available from: https://doi.org/10.1089/ars.2019.7884
Artigo de periodico
In silico mapping of essential residues in the catalytic domain of PDE5 responsible for stabilization of its commercial inhibitors (2019)
Oliveira, Ivan Pires de ; Lescano, Caroline Honaiser ; De Nucci, Gilberto
Source: Scientia Pharmaceutica. Unidade: ICB
Subjects: FARMACOLOGIA, INIBIDORES DE ENZIMAS, ENZIMAS HIDROLÍTICAS, HIDRÓLISE, CATÁLISE, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
OLIVEIRA, Ivan Pires de e LESCANO, Caroline Honaiser e DE NUCCI, Gilberto. In silico mapping of essential residues in the catalytic domain of PDE5 responsible for stabilization of its commercial inhibitors. Scientia Pharmaceutica, v. 87, n. 4, p. 14 , 2019Tradução . . Disponível em: https://doi.org/10.3390/scipharm87040029. Acesso em: 14 nov. 2024.
APA
Oliveira, I. P. de, Lescano, C. H., & De Nucci, G. (2019). In silico mapping of essential residues in the catalytic domain of PDE5 responsible for stabilization of its commercial inhibitors. Scientia Pharmaceutica, 87( 4), 14 . doi:10.3390/scipharm87040029
NLM
Oliveira IP de, Lescano CH, De Nucci G. In silico mapping of essential residues in the catalytic domain of PDE5 responsible for stabilization of its commercial inhibitors [Internet]. Scientia Pharmaceutica. 2019 ; 87( 4): 14 .[citado 2024 nov. 14 ] Available from: https://doi.org/10.3390/scipharm87040029
Vancouver
Oliveira IP de, Lescano CH, De Nucci G. In silico mapping of essential residues in the catalytic domain of PDE5 responsible for stabilization of its commercial inhibitors [Internet]. Scientia Pharmaceutica. 2019 ; 87( 4): 14 .[citado 2024 nov. 14 ] Available from: https://doi.org/10.3390/scipharm87040029

USP Schools

ReP

Filtros

Authors

Subjects

Source title

Funding Agencies

Non normalized affiliation

Countries of institutions of collaboration